H.C. Wainwright raised the firm’s price target on Lyell Immunopharma (LYEL) to $20 from $10 and keeps a Neutral rating on the shares. The firm added colorectal cancer to the company’s valuation.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL: